2.00
2.00 (0%)
As of Sep 27, 2024
Talis Biomedical Corp [TLIS]
Source:
Company Overview
Talis Biomedical Corp aimed to transform diagnostic testing by developing and commercializing innovative products that were designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases and other conditions at the point of care.
| Country | United States |
| Headquarters | chicago, illinois |
| Phone Number | (650)433-3000 |
| Industry | manufacturing |
| CEO | Robert J. Kelley |
| Website | talisbio.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $0 |
| Operating Profit | $-9.6 |
| Net Income | $-8.8 |
| Net Cash | $-17.6 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -24.3% |
| Profit as % of Stockholder Equity | -18.2% |
Management Effectiveness
| Return on Equity | -18.2% |
| Return on Assets | -12.2% |
| Turnover Ratio | |
| EBITA | $-9.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $72.7 |
| Total Liabilities | $24.1 |
| Operating Cash Flow | $-17.8 |
| Investing Cash Flow | $0.1 |
| Financing Cash Flow | $0 |
